Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Koji Sasaki, Hagop M. Kantarjian, Susan O’Brien, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William G. Wierda, Naval Daver, Alessandra Ferrajoli, Koichi Takahashi, Preetesh Jain, Mary Beth Rios, Sherry A. Pierce, Elias J. Jabbour, Jorge E. Cortes

Research output: Contribution to journalArticle

Abstract

Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) have near-normal life expectancies. With this comes the possibility of developing second cancers; we aimed to evaluate the incidence of second malignancies in patients with CML using Surveillance, Epidemiology, and End Results Program data. We identified 13,276 patients with CML newly diagnosed in 2001–2014. Patients who had prior history of cancer, a concurrent diagnosis of other malignancies in the same diagnostic year, or a second leukemia after CML diagnosis were excluded. Second malignancies were observed in 597 patients (4%) with a median follow-up of 69 months. The 5- and 10-year cumulative incidences of death for all patients were 30.5% and 41.8%. The 5- and 10-year cumulative incidences of second malignancies were 4.4% and 7.2%, respectively. The overall standardized incidence ratio (SIR) was 1.204. Increased SIRs compared to the general population were observed for the male genital system, 1.593; digestive system, 1.291; skin, 1.588; and urinary system, 1.366. Overall excess absolute risk was 1.714 per 1000 person-years at risk. Our results suggest that relative incidence of overall second malignancies in CML is slightly higher than that of the general population, with minimal increase in the excess absolute risk.

Original languageEnglish (US)
Pages (from-to)545-552
Number of pages8
JournalInternational Journal of Hematology
Volume109
Issue number5
DOIs
StatePublished - May 3 2019
Externally publishedYes

Fingerprint

Second Primary Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Incidence
SEER Program
Digestive System
Life Expectancy
Population
Neoplasms
Leukemia
Skin

Keywords

  • Chronic myeloid leukemia
  • Second malignancies
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. / Sasaki, Koji; Kantarjian, Hagop M.; O’Brien, Susan; Ravandi, Farhad; Konopleva, Marina; Borthakur, Gautam; Garcia-Manero, Guillermo; Wierda, William G.; Daver, Naval; Ferrajoli, Alessandra; Takahashi, Koichi; Jain, Preetesh; Rios, Mary Beth; Pierce, Sherry A.; Jabbour, Elias J.; Cortes, Jorge E.

In: International Journal of Hematology, Vol. 109, No. 5, 03.05.2019, p. 545-552.

Research output: Contribution to journalArticle

Sasaki, K, Kantarjian, HM, O’Brien, S, Ravandi, F, Konopleva, M, Borthakur, G, Garcia-Manero, G, Wierda, WG, Daver, N, Ferrajoli, A, Takahashi, K, Jain, P, Rios, MB, Pierce, SA, Jabbour, EJ & Cortes, JE 2019, 'Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors', International Journal of Hematology, vol. 109, no. 5, pp. 545-552. https://doi.org/10.1007/s12185-019-02620-2
Sasaki, Koji ; Kantarjian, Hagop M. ; O’Brien, Susan ; Ravandi, Farhad ; Konopleva, Marina ; Borthakur, Gautam ; Garcia-Manero, Guillermo ; Wierda, William G. ; Daver, Naval ; Ferrajoli, Alessandra ; Takahashi, Koichi ; Jain, Preetesh ; Rios, Mary Beth ; Pierce, Sherry A. ; Jabbour, Elias J. ; Cortes, Jorge E. / Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. In: International Journal of Hematology. 2019 ; Vol. 109, No. 5. pp. 545-552.
@article{d0b30ee78a4f49988081515cc8da4e63,
title = "Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors",
abstract = "Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) have near-normal life expectancies. With this comes the possibility of developing second cancers; we aimed to evaluate the incidence of second malignancies in patients with CML using Surveillance, Epidemiology, and End Results Program data. We identified 13,276 patients with CML newly diagnosed in 2001–2014. Patients who had prior history of cancer, a concurrent diagnosis of other malignancies in the same diagnostic year, or a second leukemia after CML diagnosis were excluded. Second malignancies were observed in 597 patients (4{\%}) with a median follow-up of 69 months. The 5- and 10-year cumulative incidences of death for all patients were 30.5{\%} and 41.8{\%}. The 5- and 10-year cumulative incidences of second malignancies were 4.4{\%} and 7.2{\%}, respectively. The overall standardized incidence ratio (SIR) was 1.204. Increased SIRs compared to the general population were observed for the male genital system, 1.593; digestive system, 1.291; skin, 1.588; and urinary system, 1.366. Overall excess absolute risk was 1.714 per 1000 person-years at risk. Our results suggest that relative incidence of overall second malignancies in CML is slightly higher than that of the general population, with minimal increase in the excess absolute risk.",
keywords = "Chronic myeloid leukemia, Second malignancies, Tyrosine kinase inhibitor",
author = "Koji Sasaki and Kantarjian, {Hagop M.} and Susan O’Brien and Farhad Ravandi and Marina Konopleva and Gautam Borthakur and Guillermo Garcia-Manero and Wierda, {William G.} and Naval Daver and Alessandra Ferrajoli and Koichi Takahashi and Preetesh Jain and Rios, {Mary Beth} and Pierce, {Sherry A.} and Jabbour, {Elias J.} and Cortes, {Jorge E.}",
year = "2019",
month = "5",
day = "3",
doi = "10.1007/s12185-019-02620-2",
language = "English (US)",
volume = "109",
pages = "545--552",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

AU - Sasaki, Koji

AU - Kantarjian, Hagop M.

AU - O’Brien, Susan

AU - Ravandi, Farhad

AU - Konopleva, Marina

AU - Borthakur, Gautam

AU - Garcia-Manero, Guillermo

AU - Wierda, William G.

AU - Daver, Naval

AU - Ferrajoli, Alessandra

AU - Takahashi, Koichi

AU - Jain, Preetesh

AU - Rios, Mary Beth

AU - Pierce, Sherry A.

AU - Jabbour, Elias J.

AU - Cortes, Jorge E.

PY - 2019/5/3

Y1 - 2019/5/3

N2 - Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) have near-normal life expectancies. With this comes the possibility of developing second cancers; we aimed to evaluate the incidence of second malignancies in patients with CML using Surveillance, Epidemiology, and End Results Program data. We identified 13,276 patients with CML newly diagnosed in 2001–2014. Patients who had prior history of cancer, a concurrent diagnosis of other malignancies in the same diagnostic year, or a second leukemia after CML diagnosis were excluded. Second malignancies were observed in 597 patients (4%) with a median follow-up of 69 months. The 5- and 10-year cumulative incidences of death for all patients were 30.5% and 41.8%. The 5- and 10-year cumulative incidences of second malignancies were 4.4% and 7.2%, respectively. The overall standardized incidence ratio (SIR) was 1.204. Increased SIRs compared to the general population were observed for the male genital system, 1.593; digestive system, 1.291; skin, 1.588; and urinary system, 1.366. Overall excess absolute risk was 1.714 per 1000 person-years at risk. Our results suggest that relative incidence of overall second malignancies in CML is slightly higher than that of the general population, with minimal increase in the excess absolute risk.

AB - Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) have near-normal life expectancies. With this comes the possibility of developing second cancers; we aimed to evaluate the incidence of second malignancies in patients with CML using Surveillance, Epidemiology, and End Results Program data. We identified 13,276 patients with CML newly diagnosed in 2001–2014. Patients who had prior history of cancer, a concurrent diagnosis of other malignancies in the same diagnostic year, or a second leukemia after CML diagnosis were excluded. Second malignancies were observed in 597 patients (4%) with a median follow-up of 69 months. The 5- and 10-year cumulative incidences of death for all patients were 30.5% and 41.8%. The 5- and 10-year cumulative incidences of second malignancies were 4.4% and 7.2%, respectively. The overall standardized incidence ratio (SIR) was 1.204. Increased SIRs compared to the general population were observed for the male genital system, 1.593; digestive system, 1.291; skin, 1.588; and urinary system, 1.366. Overall excess absolute risk was 1.714 per 1000 person-years at risk. Our results suggest that relative incidence of overall second malignancies in CML is slightly higher than that of the general population, with minimal increase in the excess absolute risk.

KW - Chronic myeloid leukemia

KW - Second malignancies

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85062703041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062703041&partnerID=8YFLogxK

U2 - 10.1007/s12185-019-02620-2

DO - 10.1007/s12185-019-02620-2

M3 - Article

C2 - 30830579

AN - SCOPUS:85062703041

VL - 109

SP - 545

EP - 552

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -